Literature DB >> 9366567

Constitutive activation of the gastrin-releasing peptide receptor expressed by the nonmalignant human colon epithelial cell line NCM460.

H A Ferris1, R E Carroll, M M Rasenick, R V Benya.   

Abstract

Gastrin-releasing peptide (GRP) causes multiple effects in humans by activating a specific heptaspanning receptor. Within the gastrointestinal tract, GRP receptors (GRP-R) are not normally expressed by mucosal epithelial cells except for those lining the gastric antrum. In contrast, recent studies have shown that up to 40% of resected colon cancers aberrantly express this receptor. This is important because the GRP-R can cause the proliferation of many, but not all, tissues in which it is expressed. Since GRP and other agonists are not known to exist in the colonic lumen, it has not been clear how or even if GRP-R expression in colon cancer contributes to cell proliferation. To evaluate the functional consequence of GRP-R expression on colonic epithelium, we transfected the recently isolated nonmalignant human colon epithelial cell line NCM460 with the cDNA for this receptor. All NCM460 cell lines expressing varying numbers of GRP-R bound selected agonists and antagonists indistinguishably from receptors expressed by other human tissues. Furthermore GRP-R-expressing transfected cell lines, but not wild-type NCM460 cells, proliferated independently of serum or other growth factors. Further evaluation revealed that GRP-R in these cells tonically stimulated G alpha q/11, resulting in increased phospholipase C activation. Since transfected cells do not secrete GRP, nor is their growth influenced by exposure to receptor-specific antagonists, these data indicate that GRP-R ectopically expressed by NCM460 cells are constitutively active. This report provides the first evidence of mutation-independent heptaspanning receptor constitutive activation resulting in cell proliferation, and identifies a potential mechanism whereby the GRP-R may act as an oncogene in human colon cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9366567      PMCID: PMC508453          DOI: 10.1172/JCI119795

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  Cloning and quantification of galanin-1 receptor expression by mucosal cells lining the human gastrointestinal tract.

Authors:  D D Lorimer; R V Benya
Journal:  Biochem Biophys Res Commun       Date:  1996-05-15       Impact factor: 3.575

Review 2.  Bradykinin receptors and receptor ligands (with special emphasis on vascular receptors).

Authors:  D Regoli; G Calo; A Rizzi; G Bogoni; F Gobeil; C Campobasso; G Mollica; L Beani
Journal:  Regul Pept       Date:  1996-08-27

3.  Tubulin, Gq, and phosphatidylinositol 4,5-bisphosphate interact to regulate phospholipase Cbeta1 signaling.

Authors:  J S Popova; J C Garrison; S G Rhee; M M Rasenick
Journal:  J Biol Chem       Date:  1997-03-07       Impact factor: 5.157

4.  High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer.

Authors:  T W Moody; D N Carney; F Cuttitta; K Quattrocchi; J D Minna
Journal:  Life Sci       Date:  1985-07-15       Impact factor: 5.037

5.  Location and characterization of the human GRP receptor expressed by gastrointestinal epithelial cells.

Authors:  H A Ferris; R E Carroll; D L Lorimer; R V Benya
Journal:  Peptides       Date:  1997       Impact factor: 3.750

6.  Neurohumoral control of ileal electrolyte transport. I. Bombesin and related peptides.

Authors:  J F Kachur; R J Miller; M Field; J Rivier
Journal:  J Pharmacol Exp Ther       Date:  1982-03       Impact factor: 4.030

7.  Bombesin stimulation of DNA synthesis and cell division in cultures of Swiss 3T3 cells.

Authors:  E Rozengurt; J Sinnett-Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

8.  Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer.

Authors:  F Cuttitta; D N Carney; J Mulshine; T W Moody; J Fedorko; A Fischler; J D Minna
Journal:  Nature       Date:  1985 Aug 29-Sep 4       Impact factor: 49.962

9.  Regulation of colonic ion transport by GRP. I. GRP stimulates transepithelial K and Na secretion.

Authors:  T R Traynor; S M O'Grady
Journal:  Am J Physiol       Date:  1996-03

10.  Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides.

Authors:  M J Berridge; R M Dawson; C P Downes; J P Heslop; R F Irvine
Journal:  Biochem J       Date:  1983-05-15       Impact factor: 3.857

View more
  5 in total

1.  Gα13/PDZ-RhoGEF/RhoA signaling is essential for gastrin-releasing peptide receptor-mediated colon cancer cell migration.

Authors:  Maulik Patel; Takeharu Kawano; Nobuchika Suzuki; Takao Hamakubo; Andrei V Karginov; Tohru Kozasa
Journal:  Mol Pharmacol       Date:  2014-06-23       Impact factor: 4.436

2.  Expression of GRP and its receptor is associated with improved survival in patients with colon cancer.

Authors:  Claudio A Rivera; Ned C Ahlberg; Lauren Taglia; Mayank Kumar; Adam Blunier; Richard V Benya
Journal:  Clin Exp Metastasis       Date:  2009-05-10       Impact factor: 5.150

3.  Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma.

Authors:  Jingbo Qiao; Junghee Kang; Titilope A Ishola; Piotr G Rychahou; B Mark Evers; Dai H Chung
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-27       Impact factor: 11.205

4.  Expression of V1A and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition.

Authors:  A C MacKinnon; U Tufail-Hanif; C D Lucas; D Jodrell; C Haslett; T Sethi
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

5.  Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg6,D-Trp7,9,NmePhe8]-substance P (6-11)-induced growth inhibition.

Authors:  C M Waters; A C MacKinnon; J Cummings; U Tufail-Hanif; D Jodrell; C Haslett; T Sethi
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.